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tropical or subtropical areas was determined. Thirty-one per
cent (27/86) of the subjects were faecal carriers of EPE, and 37
EPE isolates were recovered (36 Escherichia coli, 1 Klebsiella
pneumoniae). CTX-M-15 was the most prevalent enzyme (64.8%)
mainly associated with E. coli belonging to phylogroup A and
sequence type complex 10. Most of the ESBL-positive travellers
(50%) had visited countries from Asia.
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should be considered ﬁrst author.High rates of intestinal colonization with extended-spectrum
β-lactamase (ESBL)-producing Enterobacteriaceae (EPE), in
particular Escherichia coli, have been reported from many re-
gions, with CTX-M-15 being the most widespread and preva-
lent variant [1]. In the last few years, carbapenemase-producing
Enterobacteriaceae (CPE) have been increasingly reported,
with prevalence varying among countries [2]. International
travel has been previously associated with EPE carriage and
infection [3,4], but studies about the prevalence of EPE and CPE
in travellers are scarce.
We characterized and determined the prevalence of EPE and
CPE in faecal samples from 86 subjects returning from tropical
or subtropical areas and who attended our Tropical Medicine
Unit at Ramón y Cajal University Hospital (Madrid, Spain) from
September 2011 to May 2012. Written informed consent was
obtained, and subjects ﬁlled out a standardized questionnaire
about clinical and epidemiological data. Inclusion criteria were
not receiving antibiotics in the 3 months before medical
consultation and time elapsed from arrival to medical consul-
tation was less than 3 months. The study was approved by our
Hospital Ethical Committee (reference 265/10).
Each patient was classiﬁed as one of the following: 1) trav-
eller (including tourists, backpackers, aid workers, and
workers), 2) immigrants or 3) people visiting friends and rela-
tives (VFR)—that is, people who had travelled to their country
of origin to visit their friends and family. Stools of posttravel
specimens were collected within 3 days of consultation and
were screened using MacConkey agar supplemented with cef-
tazidime and cefotaxime (2 mg/L) for EPE and with Supercarba
medium for CPE [5]. One isolate per morphotype was selected
for further studies. Bacterial identiﬁcation and susceptibility
patterns were determined by the WIDER system (Fco. Soria-
Melguizo, Spain). MICs were interpreted following the
EUCAST criteria, or in their absence by using the corre-
sponding cutoff values (http://www.eucast.org).
Bacterial identiﬁcation was conﬁrmed by matrix-assisted
laser desorption-ionization time-of-ﬂight mass spectrometry
(Bruker Daltonics, Germany). ESBL and carbapenemase pro-
duction were conﬁrmed by double-disk synergy and CarbaNP
tests, respectively [6]. ESBL genes (TEM, SHV and CTX-M) wereDiseases. Published by Elsevier Ltd. All rights reserved
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further sequencing [7]. ESBL variants were assigned using data
available online (http://www.ncbi.nlm.nih.gov/, http://www.
lahey.org/studies). All ESBL-producing E. coli isolates were
typed by pulsed-ﬁeld gel electrophoresis using the PulseNet
Europe protocol (http://www.pulsenetinternational.org). Clonal
relatedness was established using 80% similarity criteria.
Phylogenetic groups among ESBL-producing E. coli were iden-
tiﬁed by multiplex PCR [8]. Multilocus sequence typing was
performed, and the corresponding sequence types (STs) were
assigned for E. coli isolates (http://mlst.warwick.ac.uk/mlst/dbs/
Ecoli) and Klebsiella pneumoniae isolates (http://www.pasteur.
fr/recherche/genopole/PF8/mlst/Kpneumoniae.html). Data
were expressed as median (interquartile range), and categorical
variables were compared by the chi-square test. Probability
values were two-tailed; a p value of 0.05 was considered to be
statistically signiﬁcant.
A total of 86 subjects were enrolled onto the study: 75
(87.2%) travellers, 8 (9.3%) VFR, and 3 (3.5%) immigrants. All
had travelled to or come from countries of Africa (30, 34.9%),
Latin America (30, 34.9%) or Asia (26, 30.2%). All epidemio-
logical data are shown in Table 1. The most common reason for
travel was tourism (n = 46), followed by aid work (n = 28).
Overall, 27 subjects (31.4%) were faecal carriers of EPE, with
24 (88.9%) of them travellers, 2 (7.4%) VFR, and 1 (3.7%)
immigrant. No faecal carriage with CPE was detected, although
its association with international travel has been reported [9].
The main limitation of our study is the impossibility of knowingTABLE 1. Epidemiological characteristics of ESBL faecal
carriers and non-faecal carriers
Characteristic ESBL No ESBL Overall
Reason for travel
Traveller 24 51 75
Tourism 10 29 39
Backpacker 2 5 7
Aid worker 12 16 28
Job 1 1
VFR 2 6 8
Immigrant 1 2 3
Origin
Africa 6 24 30
South America 6 8 14
Central America and
the Caribbean
3 20 23
Southeast Asia, India
and Nepal
12 14 26
Symptoms
Acute diarrhoea 15 21 36
Chronic diarrhoea 2 6 8
Abdominal pain 1 3 4
Fever 5 11 16
Asymptomatic 4 20 24
Age (years) 33 (29–38) 34 (14–70) 33.5 (29–40)
Sex
Male 10 28 38
Female 17 31 48
Time before consultation
(days)
7 (3–15) 15 (11–15) 15 (7–15)
Travel duration (days) 27.5 (18–90) 22.5 (14–70) 23 (15–90)
ESBL, extended-spectrum β-lactamase; VFR, visiting friends and relatives.
Data are expressed as numbers or as median (range).
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inthe pretravel EPE carriage, as our Tropical Medicine Unit only
attends subjects after travelling, and we cannot fully ensure that
the intestinal colonization by EPE occurred in the destination
area. Nevertheless, considering previous studies in Spain that
have showed a prevalence of approximately 7% to 10% of EPE
faecal carriage in the community [7,10], we assumed that the
rate in our population would be close to this value. The per-
centage found in our study (31.4%) is much higher than what
we expected and is similar to that recently observed among
healthy travellers from the Netherlands and Sweden (31.2%)
[11,12].
The most common reason among EPE faecal carriers for
travel was aid work (n = 12) and tourism (n = 10), but no
statistical signiﬁcance was found for reason for travel (Tables 1
and 2). To our knowledge, this is the ﬁrst time that aid work
and migrants appear to be associated with the acquisition of
EPE. The most visited destinations by ESBL-positive travellers
were Asia (Southeast Asia, India and Nepal) (12/24, 50%),
previously described as a high-risk travel area for acquisition of
these organisms [4,11,12]. Other destinations found in our
series were South America (4/24; 16.7%) and Central America
(3/24; 12.5%), which are areas of moderate risk [4,12,13]. The
two VFRs returned from South America, and the single immi-
grant came from Africa. No statistical signiﬁcance was found
among ESBL faecal carriage and geographic area of procedence.
The most frequent reason for medical consultation of the
ESBL faecal carriers was acute diarrhoea (three or more non-
formed stools per day for less than 2 weeks), which was pre-
sent in 55.5% (15/27) of the subjects. Only 14.8% (4/27)
patients were asymptomatic at consultation (Tables 1 and 2).
No statistical signiﬁcance was found among EPE carriage and
symptoms. However, EPE colonization has been demonstrated
in patients with traveller’s diarrhoea in studies from Europe and
Canada [3,13–15].
Thirty-seven EPE isolates were recovered: 36 E. coli (97.3%)
and one K. pneumoniae (2.7%). Molecular characterization of
these isolates is shown in Table 2. CTX-M enzymes (97.3%)
were the most prevalent ESBL type, as previously described
[14,15]. In our series, CTX-M-15 (63.2%) was the most prev-
alent enzyme and was associated with all continents, followed
by CTX-M-14 (13.2%), which was found in travellers from
South America and Southeast Asia. These ﬁndings emphasize
the global distribution of CTX-M-15 [14,16]. Interestingly,
some ESBLs were particularly associated with speciﬁc areas:
CTX-M-27 and CTX-M-32 were only found in travellers from
the Caribbean, CTX-M-55 and CTX-M-65 from South Amer-
ica, and CTX-M-2 from Southeast Asia. Nevertheless, CTX-M-
27 has been previously found in Asia [12] and CTX-M-55 in
food of animal origin in China and in travellers from Asia
[12,17].fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e1–252.e4
TABLE 2. Epidemiological characteristics of faecal carriers and corresponding ESBL-producing Enterobacteriaceae
Microorganism ESBL Phylogenetic 
group
ST (CC) Pulsotype Individual Individual 
category
Country Chief Complaint (CC) Associated resistances
E. coli CTX-M-15 A ST167 (STC10) EC5 1 Traveller (AW ) Sudan Fever Sul W
ST10 (STC10) EC6 1 Traveller (AW) Sudan Fever G T Cip Sxt Sul W
ST617 (STC10) EC2 2 Traveller (AW) Ethiopia Acute diarrhoea G T Ak Cip Sxt Sul W 
ST44 (STC10) EC7 3 Traveller (AW) Guatemala Acute diarrhoea G T Cip Sxt Sul W
ST48 (STC10) EC13 4 Traveller (TOU) India Acute diarrhoea/ Fever syndrome G T Sxt Sul W 
ST656 (STC10) EC11 5 VFR Venezuela Acute diarrhoea Nal Cip Sxt  W
ST46 (STC46) EC36 6 Traveller (AW) India Acute diarrhoea G T Nal Cip Sxt
ST1139 (STC46) EC33 7 Traveller (TOU) Nepal Fever Cip
CTX-M-15 ST2711 EC12 8 Traveller (TOU) Cambodia Fever G T Nal Cip Sxt Sul W 
CTX-M-15 B2 ST131 EC15 9 Migrant Nigeria Asymptomatic G T K Nal Cip Sxt Sul W 
EC8 10 Traveller (AW) Bolivia Acute diarrhoea Sul 
EC9 10 Traveller (AW) Bolivia Acute diarrhoea G T Nal Cip Sul
ST2252 EC22 11 Traveller (AW) Indonesia Acute diarrhoea G T Nal Cip  Sxt  
ST361 EC24 12 Traveller (TOU) Kenya Asymptomatic Nal Cip Sxt 
CTX-M-15 F ST648 EC32 14 Traveller (AW) Angola Fever G T Nal Cip Sxt 
EC16 15 Traveller (AW) India Acute diarrhoea/Abdominal pain G T Ak Nal Cip Sxt Sul W
EC17 15 Traveller (AW) India Acute diarrhoea/Abdominal pain G T Nal Cip Sxt Sul W
EC1 16 Traveller (BAC) India Acute diarrhoea G T Ak Nal Cip Sxt Sul W 
CTX-M-15 D ST38 (STC38) EC10 17 Traveller (AW) Cambodia Chronic diarrhoea T Nal Cip Sul 
ST2914 EC28 18 Traveller (TOU) India/Nepal Acute diarrhoea/Abdominal pain Cip Sxt 
ST405 (STC405) EC31 13 Traveller (AW) Mali Asymptomatic G T Nal Cip Sxt
ST507 EC14 9 Migrant Nigeria Asymptomatic T Ak Nal Cip Sxt Sul W 
CTX-M-15 E ST485 EC29 18 Traveller (TOU) India/Nepal Acute diarrhoea/Abdominal pain Nal Cip
CTX-M-32 A ST10 (STC10) EC3 19 Traveller (TOU) Cuba Acute diarrhoea Nal Cip Sxt Sul W
EC4 19 Traveller (TOU) Cuba Acute diarrhoea Cip Sxt Sul W
CTX-M-14 A ST48 (STC10) EC34 20 Traveller (TOU) Thailand Acute diarrhoea/Fever Nal Cip  Sxt
ST178 (STC10) EC35 20 Traveller (TOU) Thailand Acute diarrhoea/Fever Cip Sxt 
CTX-M-14 ST43 (STC10) EC27 21 VFR Ecuador Abdominal pain Sxt
CTX-M-14 D ST38 (STC38) EC18 22 Traveller (AW) Cambodia Chronic diarrhoea G Nal Cip Sxt 
CTX-M-27 B2 ST131 EC25 23 Traveller (TOU) Dominican 
Republic
Acute diarrhoea/Fever Nal Cip Sxt
ST1193 EC26 23 Traveller (TOU) Dominican 
Republic
Acute diarrhoea/Fever Nal Cip Sxt
CTX-M-55 A ST10 (STC10) EC20 24 Traveller (BAC) Peru Acute diarrhoea Nal Cip Sxt
CTX-M-65 E ST3057 EC19 25 Traveller (AW) Bolivia Asymptomatic G T Sxt 
CTX-M-65 B1 ST602 (STC446) EC30 26 Traveller (TOU) Colombia Acute diarrhoea/Abdominal pain Nal Cip
CTX-M-2 A ST554 (STC10) EC21 11 Traveller (AW) Indonesia Acute diarrhoea G T Nal Cip Sxt
SHV-type ST23 (STC23) EC23 27 Traveller (TOU) Philippines Fever syndrome Nal Cip 
K. pneumoniae CTX
aOnly for Escherichia coli. BAC: Backpacker; AW: Aid Work; TOU: Tourist; VFR: visiting friends and relatives.
bAid work includes: Missionary/Volunteer/Researcher. G: Gentamicin; T: Tobramicin; Ak: Amikacin; Nal: Nalidixic Acid; Cip: Ciprofloxacin; Sxt: Trimethoprim/Sulfamethoxazole; Sul: Sulfonamide;
W: Trimethoprim.
-M-15 -- ST307 KP1 9 Migrant Nigeria Asymptomatic G T Nal Cip Sxt Sul W 
252.e3 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIPulsed-ﬁeld gel electrophoresis and phylogenetic analysis
revealed 36 different E. coli pulsotypes (EC1 to EC36) belonging
to A (47.2%, n = 17), B2 (19.4%, n = 7), D (13.9%, n = 5), F
(11.1%, n = 4), E (5.6%, n = 2) and B1 (2.8%, n = 1) phylogroups.
The most prevalent STs identiﬁed were ST10 (10.8%; n = 4),
ST131 (10.8%; n = 4) and ST648 (10.8%; n = 4). Nineteen
isolates (52.8%) were assigned to a known ST complex (STC);
most of them belonged to STC10 (12/19) (Table 2). All the
isolates belonging to STC10 were classiﬁed as phylogroup A, a
complex of mainly non-virulent strains [18], and was the most
prevalent STC in the multilocus sequence typing database.
Moreover, STC10 has been described in Spain as a usual
complex among ESBL-producing E. coli isolates [19], suggesting
its involvement in the global expansion of ESBL enzymes. ST131
was associated with B2 E. coli lineage and was found in travellers
returning from different countries (Bolivia, Dominican Republic
and Nigeria); three carried CTX-M-15 ESBL. The low preva-
lence of this clone is in concordance with other studies that
analysed the colonization of returning travellers [14,20]. The
presence in our study of ST648 E. coli–producing CTX-M-15
linked to phylogroup F is noteworthy. Recently, it has been
described in companion animals and horses, with a virulence
proﬁle that is an alert for the possibility of global dissemination
of this clone [21].
Coresistance to non-β-lactam antimicrobial drugs was com-
mon in the EPE isolates; 84.5% (32/37) were resistant toClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectciproﬂoxacin, 78.4% (29/37) to trimethoprim-sulfamethoxazole,
67.6% (25/37) to nalidixic acid, 51.4% (19/37) to tobramycin,
48.6% (18/37) to gentamicin and 10.8% (4/37) to amikacin
(Table 2). Differences in resistance between nalidixic acid and
ciproﬂoxacin could be associated with expression of plasmid-
mediated, quinolone-resistant determinants [22].
In summary, a high rate of intestinal colonization with EPE
among travellers, immigrants and VFR returning to Spain,
especially from Southeast Asia and India, was observed. Our
ﬁndings support the role of international travel in the acquisition
of these organisms, which may increase the risk of dissemination
and emphasizes the importance of surveillance studies to
improve the understanding of their global epidemiology.
Although our results indicate that most of the colonization is
due to CTX-M producers, especially CTX-M-15, as others have
pointed out [13,14], the dissemination of ESBL is associated
mainly with non-ST131 clones. This contrasts with data from
other studies and with the global dissemination of ST131 E. coli
isolates worldwide [23], suggesting that other clones are also
involved in the dissemination of CTX-M enzymes.Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e1–252.e4
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